Guidant gains FDA nod for ENDOTAK ICD (implantable cardioverter defibrillator) lead:
This article was originally published in Clinica
Guidant has gained FDA go-ahead to market in the US its ENDOTAK reliance active-fixation defibrillation lead, which it says features a simplified fixation system that allows smooth deployment into the heart wall. The lead, which transmits signals between the heart and the ICD device, has fluoroscopic markers to enable surgeons to clearly see the helix-shaped tip extending into the tissue. The product will be released in the US later this month, said the firm.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.